Investigation of the effective and safe use of the drug product in the treatment of actinic keratosis with daylight

Registry ID

EUCTR2015-004382-83

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Biofrontera Bioscience GmbH

Start date

2016-03-31

Completion date

2017-09-19

Last update

2026-08-16

Conditions

• Actinic keratosis

Summary

The primary objective of the study is to compare the efficacy and safety of Ameluz® treatment of mild to moderate AK with Metvix® when using daylight PDT.

Locations

• , , Spain
• , , Germany

Related clinical trials

• An exploratory, multicenter, randomized, open-label with blind evaluation, active-controlled study to evaluate the safety and efficacy of Keramod® (imiquimod 50 mg/g, Gel) compared with Aldara® (imiquimod 50 mg/g, Cream) for the treatment of actinic keratosis in adults.

View on source registry